3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
10
Terminated
3
Recruiting
2
Withdrawn
1
Unknown
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
63
Lymphoid
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Conditions
Uterine Cervical Neoplasms
133
Ovarian Neoplasms
112
Endometrial Neoplasms
83
Uterine Cervical Dysplasia
19
Papillomavirus Infections
17
Breast Neoplasms
16
Fallopian Tube Neoplasms
15
Colorectal Neoplasms
14
Carcinoma, Ovarian Epithelial
14
Neoplasms
12
Carcinoma, Non-Small-Cell Lung
12
Vulvar Neoplasms
10
Prostatic Neoplasms
10
Neoplasm Metastasis
10
Recurrence
9
Endometrial Hyperplasia
9
Cervical Cancer Screening
9
Acquired Immunodeficiency Syndrome
8
Uterine Neoplasms
7
Stomach Neoplasms
7
Squamous Intraepithelial Lesions
6
Pancreatic Neoplasms
6
Locally Advanced Cervical Cancer
6
Head and Neck Neoplasms
6
Anus Neoplasms
6
Vaginal Neoplasms
5
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Pelvic Neoplasms
5
Interventions
trametinib
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Glioma
×
Gynecologic
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled